Rise of TRIM8: A Molecule of Duality.
E3 ubiquitin ligases
TRIM family
TRIM8
cancer
Journal
Molecular therapy. Nucleic acids
ISSN: 2162-2531
Titre abrégé: Mol Ther Nucleic Acids
Pays: United States
ID NLM: 101581621
Informations de publication
Date de publication:
04 Dec 2020
04 Dec 2020
Historique:
entrez:
24
11
2020
pubmed:
25
11
2020
medline:
25
11
2020
Statut:
epublish
Résumé
The human tripartite motif containing protein 8 (TRIM8), a member of TRIM family proteins, is known to play a dual role as both tumor suppressor and oncogene, and to function at the crosstalk of cancer and innate immunity. In this review, in addition to accumulating recent corroborations that endorse this dual character of TRIM8, we appraise the game-changing capacity of TRIM8 under stress conditions against the backdrop of cell proliferation, apoptosis, and cancer, and also highlight the duality of TRIM8 in multiple contexts like cellular localization, stress-induced conditions, and E3 ubiquitin ligase activity. Finally, we discuss the emerging role of TRIM8 during bipolar spindle formation and mitotic progression, and its growing sphere of influence across multiple human cancers and pathologies, and suggest TRIM8-linked axes that can be modulated further for anti-cancer therapeutics development.
Identifiants
pubmed: 33230447
doi: 10.1016/j.omtn.2020.08.034
pii: S2162-2531(20)30264-X
pmc: PMC7533350
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
434-444Informations de copyright
© 2020 The Author(s).
Références
J Biol Chem. 1983 Jul 10;258(13):8206-14
pubmed: 6305978
Cell Res. 2016 Apr;26(4):484-98
pubmed: 27002218
Cell Death Differ. 2020 Mar;27(3):887-902
pubmed: 31969691
Cell Metab. 2020 Apr 7;31(4):726-740.e8
pubmed: 32268115
Exp Cell Res. 2020 Mar 15;388(2):111818
pubmed: 31917201
Onco Targets Ther. 2017 Feb 24;10:1115-1122
pubmed: 28280352
Mol Cancer. 2017 Mar 21;16(1):67
pubmed: 28327152
Leukemia. 2012 Jul;26(7):1584-93
pubmed: 22343732
Ann Hum Genet. 2016 Jul;80(4):235-40
pubmed: 27346735
Cell Signal. 2018 Aug;48:1-12
pubmed: 29678622
PLoS One. 2012;7(11):e48662
pubmed: 23152791
Brain Res. 2020 Feb 1;1728:146590
pubmed: 31862654
Cell Cycle. 2015;14(6):827-37
pubmed: 25590964
Int J Biol Sci. 2019 Jun 4;15(8):1618-1629
pubmed: 31360105
J Cell Sci. 2016 Mar 1;129(5):875-80
pubmed: 26906419
J Biol Chem. 2002 Oct 4;277(40):37315-22
pubmed: 12163497
Mol Biol Cell. 2005 Jul;16(7):3187-99
pubmed: 15843429
Genes (Basel). 2017 Nov 28;8(12):
pubmed: 29182544
Int J Mol Sci. 2019 Apr 10;20(7):
pubmed: 30974870
Sci Adv. 2019 Nov 20;5(11):eaax3511
pubmed: 31799391
Am J Med Genet A. 2018 Nov;176(11):2470-2478
pubmed: 30244534
Pediatr Nephrol. 2020 Jun;35(6):1129-1132
pubmed: 32193649
Mol Oncol. 2017 Mar;11(3):280-294
pubmed: 28100038
Biochim Biophys Acta Gen Subj. 2019 Feb;1863(2):491-501
pubmed: 30528352
Proc Natl Acad Sci U S A. 2011 Nov 29;108(48):19341-6
pubmed: 22084099
Inflammation. 2017 Apr;40(2):454-463
pubmed: 27995356
J Immunol. 2017 Sep 1;199(5):1856-1864
pubmed: 28747347
Trends Biochem Sci. 2017 Apr;42(4):297-311
pubmed: 28118948
Sci Transl Med. 2015 Sep 9;7(304):304ra143
pubmed: 26355032
Clin Cancer Res. 2008 Dec 1;14(23):7583-7
pubmed: 19047082
Cancer Lett. 2020 Mar 31;473:98-106
pubmed: 31904480
Genes Chromosomes Cancer. 2017 Sep;56(9):668-680
pubmed: 28510357
Oncotarget. 2014 Sep 15;5(17):7446-57
pubmed: 25277184
Cells. 2019 May 27;8(5):
pubmed: 31137886
BMC Cancer. 2015 Jun 16;15:470
pubmed: 26077989
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Nat Commun. 2018 Apr 19;9(1):1558
pubmed: 29674694
Front Oncol. 2019 Nov 05;9:1154
pubmed: 31781486
EMBO J. 2001 May 1;20(9):2140-51
pubmed: 11331580
Cell Cycle. 2012 Feb 1;11(3):511-23
pubmed: 22262183
Int Immunopharmacol. 2020 Jun;83:106475
pubmed: 32283508
Nat Rev Immunol. 2008 Nov;8(11):849-60
pubmed: 18836477
Biochem Biophys Res Commun. 2000 Dec 20;279(2):482-6
pubmed: 11118312